Combination therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a metastatic solid tumor (cancer that has spread) that has been confirmed by a biopsy or pathology report.
- You have at least one tumor that can be measured on scans and another tumor that can be biopsied (sampled with a needle).
- You have had a taxane chemotherapy (like paclitaxel) before, and it's been at least 3 months since your last dose.
- You have tried standard treatments, or your doctor believes a clinical trial is the best next step for you.
- Your general health is good (you are up and about, able to care for yourself, with a performance status of 0 or 1).
- Your blood counts (hemoglobin, white cells, neutrophils, platelets) and kidney/liver function are within study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination therapy for people with advanced tumors that have not responded to other treatments. The goal is to see if the combination can shrink tumors and improve well-being.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
This trial tests a new combination of drugs for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and improve outcomes.
This trial tests a combination of three drugs (tislelizumab, bevacizumab, and capecitabine) for people with advanced solid tumors, including some who have not responded to immunotherapy or have brain metastases. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of three drugs (nab-paclitaxel, lenvatinib, and pembrolizumab) for people with advanced non-small cell lung cancer whose cancer grew after first-line treatment with immunotherapy and chemo. The goal is to see if this combination can help control the cancer.
Hear when a new Metastatic Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.